Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia

Authors :: Jeff P. Sharman
Miklos Egyed
Wojciech Jurczak
Alan Skarbnik
John M. Pagel
Ian W. Flinn
Manali Kamdar
Talha Munir
Renata Walewska
Gillian Corbett
Laura Maria Fogliatto
Yair Herishanu
Versha Banerji
Steven Coutre
George Follows
Patricia Walker
Karin Karlsson
Paolo Ghia
Ann Janssens
Florence Cymbalista
Jennifer A. Woyach
Emmanuelle Ferrant
William G. Wierda
Veerendra Munugalavadla
Ting Yu
Min Hui Wang
John C. Byrd
Sharman, J. P.
Egyed, M.
Jurczak, W.
Skarbnik, A.
Pagel, J. M.
Flinn, I. W.
Kamdar, M.
Munir, T.
Walewska, R.
Corbett, G.
Fogliatto, L. M.
Herishanu, Y.
Banerji, V.
Coutre, S.
Follows, G.
Walker, P.
Karlsson, K.
Ghia, P.
Janssens, A.
Cymbalista, F.
Woyach, J. A.
Ferrant, E.
Wierda, W. G.
Munugalavadla, V.
Yu, T.
Wang, M. H.
Byrd, J. C.
Publication Year :: 2022
Publisher :: Springer Nature, 2022.
Abstract: ispartof: LEUKEMIA vol:36 issue:4 pages:1171-1175 ispartof: location:England status: published

Tools